Allarity Therapeutics

OMX: ALLR

SEK180.9m market cap

SEK0.91 last close

Allarity Therapeutics is a Denmark-based biopharmaceutical company. Its patent-protected mRNA-based DRP platform enables the identification of patients with gene expression highly likely to respond to treatment. It is advancing the PARP inhibitor stenoparib (2X-121), the TKI dovitinib and microtubule inhibitor Ixempra.

Investment summary

Allarity Therapeutics holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. Allarity Therapeutics’ goal is to then develop its portfolio of drugs that are active within populations that the DRP can identify. The company recently focused its strategy on three lead assets: the tyrosine kinase inhibitor (TKI) dovitinib, the poly-ADP-ribose polymerase (PARP) inhibitor stenoparib, and the microtubule inhibitor agent Ixempra.

Y/E Dec
Revenue (DKKm)
EBITDA (DKKm)
PBT (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2018A 2.1 (32.3) (22.5) (44.00) N/A N/A
2019A 0.8 (66.5) (174.9) (208.11) N/A N/A
2020E 0.9 (103.2) (101.4) (58.85) N/A N/A
2021E 0.9 (238.3) (240.7) (116.31) N/A N/A
Industry outlook

Allarity Therapeutics and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost; it may then out-license them after clinical validation.

Last updated on 03/12/2020
Register to receive research on Allarity Therapeutics as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (DKKm) 43
Forecast gearing ratio (%) 57
Price performance
%
1m
3m
12m
Actual (35.9) (46.9) (53.2)
Relative* (40.6) (51.3) (60.1)
52-week high/low SEK3.9/SEK0.9
*% relative to local index
Key management
Duncan Moore Chairman
Steve Carchedi CEO
Henrik Moltke CFO

Content on Allarity Therapeutics